Primary Diagnosis for Fluvoxamine

Fluvoxamine is FDA-approved exclusively for the treatment of Obsessive-Compulsive Disorder (OCD) in adults. 1

FDA-Approved Indication

Fluvoxamine is indicated for the treatment of obsessions and compulsions in patients with OCD, as defined by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. 1
The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning. 1
Efficacy was established in three 10-week trials with obsessive-compulsive outpatients. 1

Multiple randomized controlled trials demonstrate fluvoxamine's superiority over placebo for OCD treatment, with response rates of 38-52% compared to 0-18% with placebo. 2
In a large multicenter trial of 160 patients, fluvoxamine (100-300 mg/day) was significantly more effective than placebo on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), with 33.3% of fluvoxamine-treated patients classified as "responders" versus 9.0% with placebo at endpoint. 3
Fluvoxamine demonstrates comparable efficacy to clomipramine for OCD but with superior tolerability, reflecting its poor affinity for adrenergic, muscarinic, cholinergic, or histaminergic receptors. 4
A head-to-head trial showed fluvoxamine was significantly superior to desipramine (a norepinephrine reuptake inhibitor) for OCD, with 11 of 21 patients responding to fluvoxamine compared to only 2 of 19 with desipramine, providing evidence that serotonin reuptake inhibition is critical to anti-obsessional efficacy. 5

While fluvoxamine has demonstrated efficacy in other conditions, these remain off-label uses:

The American Academy of Child and Adolescent Psychiatry guidelines note that fluvoxamine is among the SSRIs with empirical support for treating anxiety disorders in children and adolescents, though no specific SSRIs have FDA approval for this indication. 6
Evidence supports fluvoxamine's anxiolytic properties for treating anxiety disorders, panic disorder, and social phobia, though these are not FDA-approved indications. 6, 2

Fluvoxamine may be used as an SSRI option for major depressive disorder, though the American College of Physicians guidelines do not distinguish between second-generation antidepressants based on efficacy for depression. 6
Guidelines for Alzheimer's disease management list fluvoxamine among SSRI options for depression, with dosing of 50 mg twice daily up to 150 mg twice daily. 6

Small studies demonstrate efficacy for PTSD-associated nightmares, with improvements in combat-related dreams in veterans, though this remains an off-label use. 6

The Infectious Diseases Society of America recommends fluvoxamine only in the context of a clinical trial for ambulatory COVID-19 patients, as evidence remains insufficient despite some promising signals. 6
Recent large trials (ACTIV-6) found that fluvoxamine at both 50 mg and 100 mg twice daily did not improve time to sustained recovery in outpatients with mild to moderate COVID-19. 7, 8

Fluvoxamine requires twice-daily dosing in youth and at any dose due to its shorter half-life compared to other SSRIs. 6
Fluvoxamine has greater potential for drug-drug interactions than other SSRIs, as it inhibits multiple CYP450 enzymes (CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6). 6
Exercise caution when co-administering with alprazolam, triazolam, theophylline, or warfarin due to significant pharmacokinetic interactions. 6, 1
Fluvoxamine carries a boxed warning for suicidal thinking and behavior through age 24 years, requiring close monitoring especially in the first months of treatment. 6